Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin for Treatment-Resistant Depression and Bipolar Disorder
NCT00916552Phase 2Completed
- Start
- Sep 2009
- Primary completion
- Oct 2012
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
A Phase 2 trial of epoetin alfa in treatment-resistant depression (TRD), bipolar disorder (BD). Started Sep 2009; status: completed.
02
Drugs
epoetin alfa
03
Conditions
treatment-resistant depression (TRD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT00916552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00916552.